Індукована хіміотерапією аменорея у хворих на рак молочної залози: основні механізми та діагностичні критерії порушення функції яєчників

І. Б. Щепотін, О. С. Зотов, М. Ф. Анікусько, І. І. Любота, Р. В. Любота

Повний текст:

PDF

Посилання


Бюлетень Національного канцер-реєстру № 12 "Рак в Україні 2010-2011", Київ, 2013.

Щепотин И.Б., Зотов А.С., Любота Р. В., Аникусько Н. Ф., Любота И. И. Молекулярные типы рака грудной железы, установленные на основе иммуногистохимических маркеров: клинико-биологические особенности и прогноз течения // Клиническая онкология. - 2012. - Т. 4, № 8. - С. 1-4.

Anderson R.A., Cameron D.A. Pretreament serum anti-Mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer // Journal of Clinical Endocrinology and Metabolism. – 2011. – Vol. 96, N 5. – P. 1336-1343. https://doi.org/10.1210/jc.2010-2582

Ben-Aharon I., Bar-Joseph H., Tzarfaty G. et al. Doxorubicin-induced ovarian toxicity // Reproductive Biology and Endocrinology. – 2010. – Vol. 4, N1. – P. 8-20. https://doi.org/10.1186/1477-7827-8-20

Berliere M., Dalenc F., Malingret N. et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracyclin-based chemotherapy with or without docetaxel // BMC Cancer. – 2008. – Vol. 8. – P. 56-62. https://doi.org/10.1186/1471-2407-8-56

Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer // Journal of Clinical Oncology. – 1998. – Vol. 14, N 5. – P. 1718-1729. https://doi.org/10.1200/jco.1996.14.5.1718

Bonadonna G., Moliterni A., Zambetti M et al. 30 years' follow-up of randomised studies of adjuvant CMF in operable breast cancer // BMJ. – 2005. – Vol. 330, N10. – P. 217-220. https://doi.org/10.1136/bmj.38314.622095.8f

Brougham M.F., Crofton P.M., Johnson E.J. et al. Anti-Mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study // Journal of Clinical Endocrinology and Metabolism. – 2012. – Vol. 97, N 6. – P. 2059-2067. https://doi.org/10.1210/jc.2011-3180

Del Mastro L., Giraudi S., Levaggi A., Pronzato P. Medical approaches to preservation of fertility in female cancer patients // Expert Opinion on Pharmacotherapy. – 2011. – Vol. 12, N3. – P. 387-396. https://doi.org/10.1517/14656566.2011.522568

Devine P.J., Perreault S.D., Luderer U. Roles of reactive oxygen species and antioxidants in ovarian toxicity // Biology of Reproduction. – 2012. – Vol. 86 N2. – P. 1-10. https://doi.org/10.1095/biolreprod.111.095224

De Vos M., Devroey P., Fauser B. Primary ovarian insufficiency // Lancet. – 2010. – Vol. 376. – P. 911-920. https://doi.org/10.1016/s0140-6736(10)60355-8

Domingo J., Guillen V., Ayllon Y. et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment // Fertility and Sterility. – 2012. – Vol. 97, N4. – P. 930-934. https://doi.org/10.1016/j.fertnstert.2012.01.093

Gracia C.R., Sammel M.D., Freeman E.W. et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. // Menopause. – 2005. – Vol. 12, N2. – P. 128-135. https://doi.org/10.1097/00042192-200512020-00005

Goldhirsch A., GelberR., Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: the international breast cancer study group // Ann Oncol. – 1990. – Vol. 9, N1. – P. 183-188.

Goldhirsh A., Wood W.C., Coates A.S. and Panel members. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer // Annals of Oncology. – 2011. – Vol. 22, N8. – P. 1736-1747. https://doi.org/10.1093/annonc/mdr304

Goodwin P.J., Pritchard K.I., Trudeau M., Hood N. Risk of menopause during the first year after breast cancer diagnosis // Journal of Clinical Oncology. – 1999. – Vol. 17, N8. – P. 2365-2370. https://doi.org/10.1200/jco.1999.17.8.2365

Johnson J., Canning J., Kaneko T., Pru J.K., Tilly J.L. Germline stem cells and follicular renewal in the postnatal mammalian ovary // Nature. – 2004. – Vol. 428, N 4. – P. 145-150. https://doi.org/10.1038/nature02316

Kelsey T.W., Wallace W.H. Human ovarian reserve from conception to menopause // PLoS ONE. – 2010. – Vol. 5, N1. – P. 1-9. https://doi.org/10.1371/journal.pone.0008772

La Marca A., Broekmans F.J., Volpe A. et al. Anti-Mullerian hormone (AMH): what do we still need to know? // Human Reproduction. – 2009. – Vol. 24, N9. – P. 2264-2275. https://doi.org/10.1093/humrep/dep210

Lambalk C.B., van Disseldorp J., de Koning C.H., Broekmans F.J. Testing ovarian reserve to predict age at menopause // Maturitas. – 2009. – Vol. 63, N4. – P. 280-291. https://doi.org/10.1016/j.maturitas.2009.06.007

Lee S., Kil W.J., Chun M. et al. Chemotherapy-related amenorrhea in premenopausal women with breast cancer // Menopause. – 2009. – Vol. 16, N1. – P. 98-103. https://doi.org/10.1097/gme.0b013e3181844877

Martin M., Pienkowski T., Mackey J. et al. Adjuvant docetaxel for node-positive breast cancer // N. Engl. J. Med. – 2005. – Vol. 352, N22. – P. 2302-2312. https://doi.org/10.1056/nejmoa043681

Meirow D., Biederman H., Anderson R.A., Wallace W.H. Toxicity of chemotherapy and radiation on female reproduction // Clinical Obstetrics and Gynecology. – 2010. – Vol. 53, N4. – P. 727-739. https://doi.org/10.1097/grf.0b013e3181f96b54

Meirow D., Dor J., Kaufman B. et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury // Human Reproduction. – 2007. – Vol. 22, N2. – P. 1626-1633. https://doi.org/10.1093/humrep/dem027

Meirow D., Lewis H., Nugent D., Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool // Human Reproduction. – 1999. – Vol. 14, N7. – P. 1903-1907. https://doi.org/10.1093/humrep/14.7.1903

National Comprehensive Cancer Network – Breast Cancer Guidelines 2011 // https://www.nccn.org/, accessed June. – 2011.

Oktay K., Oktem O., Reh A., Vahdat L. Measuring the impact of chemotherapy on fertility in women with breast cancer // Journal of Clinical Oncology. – 2006. – Vol. 24, N24. – P. 4044-4046. https://doi.org/10.1200/jco.2006.06.9823

Oktem O., Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function // Cancer. – 2007. – Vol. 110, N10. – P. 2222-2229. https://doi.org/10.1002/cncr.23071

Partridge A., Gelber S., Peppercorn J. et al. Fertility and menopausal outcomes in young breast cancer survivors // Clin Breast Cancer. – 2008. – Vol. 8, N 1. – P. 65-69. https://doi.org/10.3816/cbc.2008.n.004

Partridge A., Ruddy K., Gelber S. et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer // Fertility and Sterility. – 2010. – Vol. 94, N2. – P. 638-644. https://doi.org/10.1016/j.fertnstert.2009.03.045

Pritchard K., Levine M., Bramwell V. et al. A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer. update of NCIC CGT MA5 (national cancer institute of Canada clinical trials group trial MA5) // J. Clin. Oncol. – 2005. – Vol. 23, N22. – P. 5166-5170. https://doi.org/10.1200/jco.2005.09.423

Roche H., Fumoleau P., Spielmann M. et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial // J. Clin. Oncol. – 2006. – Vol. 24, N36. – P. 5664-5671. https://doi.org/10.1200/jco.2006.07.3916

Rosendahl M., Andersen C.Y., La Cour Freiesleben N. et al. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age // Fertility and Sterility. – 2010. – Vol. 94, N1. – P. 156-166. https://doi.org/10.1016/j.fertnstert.2009.02.043

Schover L.R. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility // Journal of Clinical Oncology. – 2008. – Vol. 26, N5. – P. 753-758. https://doi.org/10.1200/jco.2007.14.1655

Sowers M.R., Eyvazzadeh A.D., McConnell D. et al. Anti-Mullerian Hormone and Inhibin B in the Definition of Ovarian Aging and the Menopause Transition // Journal of Clinical Endocrinology and Metabolism. – 2008. – Vol. 93, N9. – P. 3478-3483. https://doi.org/10.1210/jc.2008-0567

Su H. Measuring ovarian function in young cancer survivors // Minerva Endocrinol. – 2010. – Vol. 35, N4. – P. 259-270.

Su H.I., Sammel M.D., Green J. AntiMullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors // Cancer. – 2010. – Vol. 116, N3. – P. 592-599. https://doi.org/10.1002/cncr.24746

Sukumvanich P., Case L.D., van Zee K. et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study // Cancer. – 2010. – Vol. 116, N13. – P. 3102-3111. https://doi.org/10.1002/cncr.25106

Swain S.M., Jeong J.H., Geyer C.E. Jr. et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer // N. Engl. J. Med. – 2010. – Vol. 362, N22. – P. 2053-2065. https://doi.org/10.1056/nejmoa0909638

Tsai-Turton M., Luong B.T., Tan Y., Luderer U. Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion // Toxicological Sciences. – 2007. – Vol. 98, N1. – P. 216-230. https://doi.org/10.1093/toxsci/kfm087

van Disseldorp J., Faddy M.J., Themmen A.P. Relationship of serum antimüllerian hormone concentration to age at menopause // Journal of Clinical Endocrinology and Metabolism. – 2008. – Vol. 93, N6. – P. 2129-2134. https://doi.org/10.1210/jc.2007-2093

van Montfrans J.M., Hoek A., van Hooff M.H. Predictive value of basal follicle-stimulating hormone concentrations in a general subfertility population // Fertility and Sterility. – 2000. – Vol. 74, N1. – P. 97-103. https://doi.org/10.1016/s0015-0282(00)00560-4

Walshe J.M., Denduluri N., Swain S.M. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer // Journal of Clinical Oncology. – 2006. – Vol. 24, N36. – P. 5769-5779. https://doi.org/10.1200/jco.2006.07.2793


Пристатейна бібліографія ГОСТ






DOI: https://doi.org/10.24026/1818-1384.2(43).2013.77474

Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

© Клінічна ендокринологія та ендокринна хірургія.

ISSN: 1818-1384 (Print), e-ISSN: 2519-2582, DOI: 10.24026/1818-1384.

При копіюванні активне посилання на матеріал обов'язкове.

Flag Counter